Japan Earthquake: Pharma Reacts to the Japanese Earthquake
Japanese pharma has been quick to offer donations and support in the wake of the country's environmental disaster. The rest of the world seems to have its eye on the longer-term implications.
» MORE

The Cost of New Drug R&D: When Will the Numbers Add Up?
An ongoing debate has journalists, investment analysts, pharma companies, and economists all stating the "facts" about the cost of new drug R&D. But if the numbers and data are indisputable, why are there two opposing conclusions?
» MORE

FDA Outlines Reponses to Public Health Threats
Commissioner Margaret Hamburg stresses the importance of medical countermeasures for responding to natural and deliberate threats to public health.
» MORE

Raising the Outsourcing Bar
The stakes for successfully managing the outsourced relationship have never been higher, writes Patricia Van Arnum.
» MORE

Burden of Proof
Building credibility with physicians requires trust, knowledge and enough evidence to make a powerful point.
» MORE

From Market to Market
Not all territories are alike, okay? The faster companies develop regional approaches to sales, the quicker they’ll be able to react to changing conditions.
» MORE

Growing Stronger After the Storm
To manage through a resource-constrained environment, it is essential to get the most out of procurement planning.
» MORE